Latest Research Reports

Belimumab: The frontrunner in Lupus clinical trials

Belimumab: The frontrunner in Lupus clinical trials

The US and the UK see a high percentage of CDT+ CDI cases

The US and the UK see a high percentage of CDT+ CDI cases

Emerging rivals in CAR-T cell therapies

Emerging rivals in CAR-T cell therapies

Japan leads in preventing CDI recurrences

Japan leads in preventing CDI recurrences

The quest for efficient and cost-effective R&D remains a challenge

The quest for efficient and cost-effective R&D remains a challenge

AEDs targeting rare epilepsy syndromes set to shoot to top of the market

AEDs targeting rare epilepsy syndromes set to shoot to top of the market

US faces high, growing burden of CDI

US faces high, growing burden of CDI

Despite challenges, pain-related indications are most frequently researched clinical trials

Despite challenges, pain-related indications are most frequently researched clinical trials

Will Orencia be able to compete in an already crowded market?

Will Orencia be able to compete in an already crowded market?

Chlamydia testing, one step back but two steps forward

Chlamydia testing, one step back but two steps forward

Non-industry trials were more frequent than industry trials in 2016

Non-industry trials were more frequent than industry trials in 2016

Which class of drugs is set to have the biggest impact on the cancer market?

Which class of drugs is set to have the biggest impact on the cancer market?

Monoclonal antibodies make up seven out of the top ten investigated drugs in 2016

Monoclonal antibodies make up seven out of the top ten investigated drugs in 2016

Novartis, Pfizer, Amgen, and Merck: key players in the autoimmune biosimilars space

Novartis, Pfizer, Amgen, and Merck: key players in the autoimmune biosimilars space

EMA set to approve plethora of oncology drugs

EMA set to approve plethora of oncology drugs

Top indications and therapy areas for 2012-2016 clinical trials in Israel

Top indications and therapy areas for 2012-2016 clinical trials in Israel

Orphan cancer drugs take up 37% of market share

Orphan cancer drugs take up 37% of market share

US and UK stand out with higher disease prevalence of two autoimmune diseases

US and UK stand out with higher disease prevalence of two autoimmune diseases

Is diagnosed non-invasive ductal carcinoma in-situ breast cancer rarer in China?

Is diagnosed non-invasive ductal carcinoma in-situ breast cancer rarer in China?

Anticipated approval timeline of PARP inhibitors in HER2-negative breast cancer

Anticipated approval timeline of PARP inhibitors in HER2-negative breast cancer

A look at atrial fibrillation’s market size forecast

A look at atrial fibrillation’s market size forecast